380 for heterogeneity). However, for Female population (7 studies), no significant associations were observed for both type C vs Type A (OR = 0.92; 95% CI = 0.84-1.16; P = 0.003 for heterogeneity) or types B and C combined vs Type A (OR = 0.85; 95% CI = 0.71-1.02; P = 0.000 for heterogeneity) (Figure 4). Figure 4 click here Forest plot (random-effects model) of lung cancer risk associated with CYP1A1 MspI for the combined types B and C vs Type A stratified by gender of population. Thirteen [24, 31, 47, 56, 59–61, 64, 72, 75, 78] out of 64 studies included the association of CYP1A1 MspI genotype

and lung caner risk stratified by smoking status (non-smokers or never smokers and smokers). For smokers, significantly increased risks were observed for both type C vs Type A (OR = 1. 62; 95% CI = 1.33-1.96; P = 0.000 Belnacasan for heterogeneity), types B and C combined vs Type A (OR = 1.75; 95% HSP inhibitor CI = 1.44-2.13; P = 0.003 for heterogeneity). However, for non-smokers, no significant associations were observed for both type C vs Type A (OR = 1.18; 95% CI = 0.96-1.186; P = 0.086 for heterogeneity) or types B and C combined vs Type A (OR = 1.09; 95% CI = 0.90-1.33; P = 0.114 for heterogeneity) (Figure 5). Figure

5 Forest plot (random-effects model) of lung cancer risk associated with CYP1A1 MspI for the combined types B and C vs Type A stratified by smoking status of population. 3.2.2 Association of CYP1A1 exon7 variant with lung cancer risk For all studies in the meta-analysis, the genotype, an increased risk for lung cancer was associated with 2 exon7 variants (for Val/Val vs Ile/Ile: OR = 1.24, 95% CI = 1.09-1.42, P = 0.004 for heterogeneity; for Ile/Val and Val/Val combined vs Ile/Ile: OR = 1.15, 95% CI = 1.07-1.24, P = 0.000 for heterogeneity) (Figure 6). Figure 6 Forest plot (random-effects model) of lung cancer risk associated with CYP1A1 exon7 genotype for the combined Ile/Val and Val/Val vs Ile/Ile. In the stratified analysis by ethnicity, the

risk Carteolol HCl was higher in Asian carriers of Val/Val vs Ile/Ile (OR = 1.22, 95% CI = 1.16-1.59; P = 0.016 for heterogeneity), Ile/Val and Val/Val combined vs Ile/Ile (OR = 1.21, 95% CI = 1.09-1.34; P = 0.000 for heterogeneity). A significant association was also observed in Caucasian carriers of Val/Val vs Ile/Ile (OR = 1.24; 95% CI = 1.17-1.43; P = 0.090 for heterogeneity) and Ile/Val and Val/Val combined vs Ile/Ile (OR = 1.28; 95% CI = 1.12-1.45; P = 0.000 for heterogeneity). However, no significant associations were observed in mixed populations for both Val/Val vs Ile/Ile (OR = 0.84; 95% CI = 0.77-1.03; P = 0.090 for heterogeneity) or Ile/Val and Val/Val combined vs Ile/Ile (OR = 0.92; 95% CI = 0.79-1.06; P = 0.001 for heterogeneity) (Table 2).